$SQFT Income Statement | Understand Stock

$SQFT

$0.76 -$0.04 (4.99%) Close

$SQFT Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Operations

In millions of USD; shares in millions, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Revenues:
Rental income
Fees and other income
Total revenue
Costs and expenses:
Rental operating costs
General and administrative
Depreciation and amortization
Impairment of real estate assets
Asset Impairment Charges
Total costs and expenses
Other income (expense):
Interest expense - mortgage notes
Mortgage Notes
Notes Payable

Gain on sale of marketable securities, net
Interest and other income, net
Gain on extinguishment of government debt
Deferred offering costs
Gain on sales of real estate, net
Net loss in Conduit Pharmaceuticals marketable securities (see footnote 9)
All Other Than Conduit
Conduit Pharmaceuticals Inc
Total net loss in Conduit Pharmaceuticals marketable securities (see footnote 9)
Gain on deconsolidation of SPAC (see footnote 9)
Income tax (expense) benefit
Total loss, net
Net loss:
Less: Income attributable to noncontrolling interests
Net loss attributable to Presidio Property Trust, Inc. stockholders
Less: Preferred Stock Series D dividends
Less: Series A Warrant dividend
Net loss attributable to Presidio Property Trust, Inc. common stockholders

Net loss per share attributable to Presidio Property Trust, Inc. common stockholders:
Weighted average number of common shares outstanding - basic and diluted (in shares)
Basic & Diluted (in dollars per share)
Weighted average number of common shares outstanding - basic & dilutive (in shares)

Comments